Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PT Tanabe Indonesia, Mitsubishi Tanabe Pharma's consolidated subsidiary, has launched a human TNF alpha monoclonal antibody, gilimumab, under the brand name, Simponi Subcutaneous Injection in Indonesia.
Subscribe to our email newsletter
Simponi subcutaneous injection is indicated for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Janssen Biotech discovered and developed Simponi as a treatment for inflammatory autoimmune diseases involving TNF alpha such as rheumatoid arthritis which was first approved in the US and Europe in 2009.
After receiving Japanese approval, Mitsubishi Tanabe and Janssen Pharmaceutical stated co-marketing Simponi in 2011.